Gastrointestinal Drugs Market Global Briefing 2017

Gastrointestinal Drugs Market Global Briefing 2017

  • August 2017
  • 33 pages
  • Report ID: 5057817
The gastrointestinal diseases drugs market covers medicines used for the treatment of ulcerative colitis, diverticular disease, perianal infections, anal fissures, hemorrhoids, constipation, and irritable bowel syndrome. The key gastrointestinal diseases drug categories include Anti-peptic agents (antacids, antagonists, Proton Pump Inhibitors, Sucralfate, and Misoprostol), antiemetics, adsorbents, anticholinergics, opiates, intestinal flora modifiers, emollient/surfactants, hyperosmotic, saline, and simulant/irritant.

The global gastrointestinal drugs market is expected to reach around $60 billion in 2020. This can be attributed to the expected increase in prevalence of obesity and digestive diseases globally.

Tranexamic Acid To Treat Gastrointestinal Bleeding - Drug manufacturing companies are offering tranexamic acid for the treatment of acute gastrointestinal bleeding. Tranexamic acid is a medication used to treat or prevent excessive blood loss from major trauma or surgery and is now finding applications for gastrointestinal diseases. Tranexamic acid reduces clot breakdown, thus reducing the duration and amount of bleeding. This reduces mortality rate (from 10% to 7.5%) and the probability of blood transfusion by about 30%. Major companies manufacturing tranexamic acid include Abbott Laboratories, Pfizer, GlaxoSmithKline and Bayer AG.

We are very sorry, but an error occurred.
Please contact if the problem remains.

Country=World Industry=OTC ParentIndustry=Pharmaceutical Date=201708 Topic=MarketReport Publisher=TheBusinessResearchCompany Price=1000